Modalis Therapeutics Corporation (TYO:4883)
Japan · Delayed Price · Currency is JPY 90.00
+1.00 (1.12%)
Aug 19, 2025, 10:44 AM JST
Modalis Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
6.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 40.00M | 39.00M | 3,900.00% |
| Dec 31, 2021 | 1.00M | -341.00M | -99.71% |
| Dec 31, 2020 | 342.00M | -302.00M | -46.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.22B |
| Takeda Pharmaceutical Company | 4,480.25B |
| Daiichi Sankyo Company | 1,924.68B |
| HOYA Corporation | 876.09B |
| Otsuka Holdings | 2,401.70B |
| Terumo | 1,037.94B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |
Modalis Therapeutics News
- 2 months ago - SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy - Financial Post